Access the full text.
Sign up today, get DeepDyve free for 14 days.
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
Abstract Since 1992 the USPTO has been issuing gene patents based on the premise that a gene sequence consists of patentable subject matter and meets the requirements set forth in 35 USC § 101 et seq. Various scholars and international societies have recently questioned the USPTO's stance, raising both normative concerns as well substantive problems associated with the number and scope of gene patents on the availability and access of diagnostic tests as well as their effect on scientific innovation and method validation. This paper examines recent Congressional testimony, USPTO's deference to Congress' inaction, and the possibility of judicial remedy through currently pending litigation of Association for Molecular Pathology et. al. v. United States Patent and Trademark Office, et. al. The author argues that the pending litigation may, and should, break the current stalemate and prompt re-examination of the current US patenting guidelines to arrive at a solution that integrates important policy considerations related to innovation, access, and validation.
Journal of international biotechnology law – de Gruyter
Published: Sep 1, 2009
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.